The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer<i>in vivo</i>Frank P. Vendetti, Christopher J. Bakkenist|Oncotarget|2015Cited by 240
Chemoptogenetic damage to mitochondria causes rapid telomere dysfunctionWei Qian, Bennett Van Houten, Sruti Shiva et al.|Proceedings of the National Academy of Sciences|2019Cited by 148
ATR kinase inhibition induces unscheduled origin firing through a Cdc7-dependent association between GINS and And-1Tatiana N. Moiseeva, Christopher J. Bakkenist|Nature Communications|2017Cited by 104
Pharmacologic ATM but not ATR kinase inhibition abrogates p21-dependent G1 arrest and promotes gastrointestinal syndrome after total body irradiationFrank P. Vendetti, Christopher J. Bakkenist|Scientific Reports|2017Cited by 20
A quasi-quantitative dual multiplexed immunoblot method to simultaneously analyze ATM and H2AX phosphorylation in human peripheral blood mononuclear cellsChristopher J. Bakkenist, John C. Schmitz|Oncoscience|2015Cited by 18